Pharma and BioTech Daily
Pharma & Biotech Daily is a short, AI-generated, human-supervised briefing on what’s important in pharma and biotech.
Each weekday we condense key news on pipelines, deals, regulation and strategy into a quick audio update for people who build, run and invest in life sciences.
Produced by OWITH.ai, a boutique AI & data studio.
Sponsor the show: https://sponsor.owith.ai
Pharma and BioTech Daily
Latest Episodes
Roche Acquires PathAI for $1B: AI-Driven Diagnostics Revolution | Pharma and Biotech Daily
Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. In a rapidly evolving industry landscape, artificial intelligence has emerged as a game-changer, transforming how...
Bayer's $2.4B Perfuse Deal Shakes Up Eye Care | Pharma and Biotech Daily
Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. The industry is buzzing with significant shifts driven by scientific advancements, strategic acquisitions, and re...
Sanofi Invests $294M in AI, FDA Approves Auvelity | Pharma and Biotech Daily
Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today's episode dives into the ever-evolving landscape of the pharmaceutical and biotechnology industries, which a...
Pfizer's $300M Biologics Boost & FDA's Veppanu Approval | Pharma and Biotech Daily
Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we're diving into a series of significant updates that highlight the dynamic nature of our industry, driven...
AstraZeneca's $5B Setback: FDA Rejects New Cancer Drug | Pharma and Biotech Daily
Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into the transformative dynamics shaping the industry, from financial innovations to regulatory hu...